"It's [GCC] a very big indicator of risk – higher than any other risk factors that were evaluated in this patient population."

— John Schafer, president/CEO of DiagnoCure, discussing the Guanylyl cyclase C biomarker, "Study validates DiagnoCure's colon cancer staging test."

No Comments